Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney - PubMed
- ️Fri Jan 01 2016
Arndt Manzel 2 , Nadja Grobe 3 , Eva Königshausen 4 , Christopher C Kaltenecker 1 , Johannes J Kovarik 1 , Johannes Stegbauer 4 , Susan B Gurley 5 , Dunja van Oyen 6 , Marlies Antlanger 1 , Michael Bader 7 , Daisy Motta-Santos 8 , Robson A Santos 9 , Khalid M Elased 3 , Marcus D Säemann 1 , Ralf A Linker 2 , Marko Poglitsch 6
Affiliations
- PMID: 27649628
- PMCID: PMC5030486
- DOI: 10.1038/srep33678
Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney
Oliver Domenig et al. Sci Rep. 2016.
Abstract
Cardiovascular and renal pathologies are frequently associated with an activated renin-angiotensin-system (RAS) and increased levels of its main effector and vasoconstrictor hormone angiotensin II (Ang II). Angiotensin-converting-enzyme-2 (ACE2) has been described as a crucial enzymatic player in shifting the RAS towards its so-called alternative vasodilative and reno-protective axis by enzymatically converting Ang II to angiotensin-(1-7) (Ang-(1-7)). Yet, the relative contribution of ACE2 to Ang-(1-7) formation in vivo has not been elucidated. Mass spectrometry based quantification of angiotensin metabolites in the kidney and plasma of ACE2 KO mice surprisingly revealed an increase in Ang-(1-7), suggesting additional pathways to be responsible for alternative RAS activation in vivo. Following assessment of angiotensin metabolism in kidney homogenates, we identified neprilysin (NEP) to be a major source of renal Ang-(1-7) in mice and humans. These findings were supported by MALDI imaging, showing NEP mediated Ang-(1-7) formation in whole kidney cryo-sections in mice. Finally, pharmacologic inhibition of NEP resulted in strongly decreased Ang-(1-7) levels in murine kidneys. This unexpected new role of NEP may have implications for the combination therapy with NEP-inhibitors and angiotensin-receptor-blockade, which has been shown being a promising therapeutic approach for heart failure therapy.
Figures

(a) Kidney angiotensin concentrations of wild-type (C57BL/6) and ACE2 knockout (ACE2 KO) mice (pg/g gram net weight). n = 8 mice per group. Data presented as mean ± s.d. Two-tailed Student’s t-test. *P < 0.05 **P < 0.01 ***P < 0.001 vs. wild-type. (b) Relative mRNA abundance (to beta actin) of renin in murine renal medulla (dark grey) and cortex (light grey) of wild-type and ACE2 KO. n = 8 mice per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA). *P < 0.05 vs. medulla. (c) Renal renin activity of wild-type (black) ACE2 KO (white) assayed by Ang I formation determination in homogenates following recombinant murine angiotensinogen spiking. n = 4 mice per group. Data presented as mean ± s.d. Two-tailed Student’s t-test. not significant (NS) vs. wild-type.

Analysis of angiotensin metabolism in kidney homogenates of mice (a–c) and human (d–f ). (a) Renal Ang II turnover to Ang-(1-7) of wild-type (black) and ACE2 KO mice (white) in presence and absence of specific inhibitors. n = 4 per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA). *P < 0.001 within wild-type group vs. solvent control. (b) Ang I turnover to Ang-(1-7) (left) and Ang II (right) of wild-type (black) and ACE2 KO (white). n = 4 per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA). *P < 0.001 vs. solvent control. (c) Enzymatic contribution to Ang II or Ang-(1-7) formation in mice was calculated on the inhibitor sensitive angiotensin formation rate of fig. 2a,b. Data presented as mean ± s.d. (d) Human renal Ang II turnover to Ang-(1-7) in presence and absence of specific inhibitors. n = 5 per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA). *P < 0.001 vs. solvent control. (e) Human Ang I turnover to Ang-(1-7) (left) and Ang II (right) in kidney homogenates. n = 5 per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA). *P < 0.001 vs. solvent control. (f) Enzymatic contribution to Ang II or Ang-(1-7) formation in human was calculated on the inhibitor sensitive angiotensin formation rate of fig. 2d,e. Data presented as mean ± s.d.

(a) Diminishing effect of increasing DL-thiophan concentrations (0 μM – 100 μM) on local turnover of Ang I to Ang-(1-7) is shown by MALDI-Imaging. Brighter colors of the murine kidney section indicate pronounced Ang-(1-7) formation in the renal cortex. (b) Increasing Ang-(1-7) signals depending on lisinopril concentration (0 μM–10 μM). (c) Inhibitory capacity of 100 μM DL-thiorphan on Ang I to Ang-(1-7) turnover in presence of 10 μM lisinopril (d) Intensity of Ang-(1-7) formation (Fig. 3c) was calculated and is given in bars. n = 4 per group. Data presented as mean ± s.d. Two-tailed Student’s t-test. *P < 0.05 vs. 10 μM lisinopril. (e) Schematic graph highlights the targeted angiotensin pathways of the used inhibitors.
Similar articles
-
Critical Role of Neprilysin in Kidney Angiotensin Metabolism.
Kaltenecker CC, Domenig O, Kopecky C, Antlanger M, Poglitsch M, Berlakovich G, Kain R, Stegbauer J, Rahman M, Hellinger R, Gruber C, Grobe N, Fajkovic H, Eskandary F, Böhmig GA, Säemann MD, Kovarik JJ. Kaltenecker CC, et al. Circ Res. 2020 Aug 14;127(5):593-606. doi: 10.1161/CIRCRESAHA.119.316151. Epub 2020 May 18. Circ Res. 2020. PMID: 32418507
-
Herath CB, Lubel JS, Jia Z, Velkoska E, Casley D, Brown L, Tikellis C, Burrell LM, Angus PW. Herath CB, et al. Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G98-G106. doi: 10.1152/ajpgi.00045.2009. Epub 2009 Apr 23. Am J Physiol Gastrointest Liver Physiol. 2009. PMID: 19389807 Free PMC article.
-
Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Rice GI, et al. Biochem J. 2004 Oct 1;383(Pt 1):45-51. doi: 10.1042/BJ20040634. Biochem J. 2004. PMID: 15283675 Free PMC article.
-
ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE, Chiong M, Lavandero S, Ocaranza MP. Mendoza-Torres E, et al. Ther Adv Cardiovasc Dis. 2015 Aug;9(4):217-37. doi: 10.1177/1753944715597623. Epub 2015 Aug 13. Ther Adv Cardiovasc Dis. 2015. PMID: 26275770 Review.
-
Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Santos RA, et al. J Endocrinol. 2013 Jan 18;216(2):R1-R17. doi: 10.1530/JOE-12-0341. Print 2013 Feb. J Endocrinol. 2013. PMID: 23092879 Review.
Cited by
-
Masters AK, Ward JL, Guillot E, Domenig O, Yuan L, Mochel JP. Masters AK, et al. PLoS One. 2024 Feb 23;19(2):e0298030. doi: 10.1371/journal.pone.0298030. eCollection 2024. PLoS One. 2024. PMID: 38394253 Free PMC article.
-
Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation.
Kovarik JJ, Kaltenecker CC, Kopecky C, Domenig O, Antlanger M, Werzowa J, Eskandary F, Kain R, Poglitsch M, Schmaldienst S, Böhmig GA, Säemann MD. Kovarik JJ, et al. Sci Rep. 2019 Jul 5;9(1):9762. doi: 10.1038/s41598-019-46114-x. Sci Rep. 2019. PMID: 31278281 Free PMC article.
-
Miller M, Quimby J, Langston C, Ames M, Parker VJ. Miller M, et al. J Vet Intern Med. 2022 Sep;36(5):1693-1699. doi: 10.1111/jvim.16499. Epub 2022 Aug 13. J Vet Intern Med. 2022. PMID: 35962709 Free PMC article.
-
Larouche-Lebel É, Loughran KA, Huh T, Oyama MA. Larouche-Lebel É, et al. J Vet Intern Med. 2021 Jan;35(1):22-32. doi: 10.1111/jvim.16025. Epub 2020 Dec 24. J Vet Intern Med. 2021. PMID: 33368659 Free PMC article.
-
Hammad FT, Al-Salam S, AlZaabi SS, Alfalasi MM, Hammad AF, Yasin J, Lubbad L. Hammad FT, et al. Physiol Rep. 2021 Mar;9(6):e14723. doi: 10.14814/phy2.14723. Physiol Rep. 2021. PMID: 33719192 Free PMC article.
References
-
- Udani S., Lazich I. & Bakris G. L. Epidemiology of hypertensive kidney disease. Nat. Rev. Nephrol. 7, 11–21 (2011). - PubMed
-
- Hodgson T. A. & Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med. Care 39, 599–615 (2001). - PubMed
-
- Yamout H., Lazich I. & Bakris G. L. Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease. Adv. Chronic Kidney Dis. 21, 281–286 (2014). - PubMed
-
- Ptinopoulou A. G., Pikilidou M. I. & Lasaridis A. N. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. Hypertens. Res. 36, 91–101 (2012). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous